In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Association between length of stay and mortality or readmission in patients with acute heart failure

Session Poster Session 3

Speaker Pajaree Sriparn

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : P Sriparn (Bangkok,TH), M Anuntasainont (Bangkok,TH), C Thimphitthaya (Bangkok,TH), P Lalitnithi (Bangkok,TH), S Kittiprachakul (Bangkok,TH), A Trongtorsak (Bangkok,TH), A Ariyachaipanich (Bangkok,TH)

Authors:
P Sriparn1 , M Anuntasainont1 , C Thimphitthaya1 , P Lalitnithi1 , S Kittiprachakul1 , A Trongtorsak1 , A Ariyachaipanich1 , 1Chulalongkorn University - Bangkok - Thailand ,

Citation:

Background: Length of stay (LOS) in acute heart failure (AHF) varies between patients as it reflexes the counterbalance of optimising patient’s condition and avoiding intra-hospital complication. However, Its prognostic significance has not been well studied.

Purpose: We aim to assess whether LOS associates with short and long term all-cause mortality or readmission in AHF patients.

Methods: We conducted a prospective cohort study of 191 consecutive patients who were discharged with admission diagnosis of AHF between July 2017 and March 2018. The patients were categorised into 3 groups by LOS: short, intermediate and long LOS (duration of admission 1-4, 5-10 and = 11 days, respectively). The outcomes were 30 and 180-day all-cause mortality or readmission rate. Pearson’s chi-squared test was used to analyse.

Results: Total of 191 patients(mean age 68.4 years, 46.6% female) were included. Patient’s baseline characteristics (age, gender, left ventricular ejection fraction, NYHA classification and co-morbidities) were similar in the 3 groups. The 30-day outcome (all-cause mortality or readmission) was not different between short, intermediate and long LOS group (25.8%, 19% and 21%, respectively; p= 0.637). The 180-day outcome was significantly different with the lowest rate of all-cause mortality or readmission in the intermediate LOS group (56.1%, 38.1% and 58.1%; p=0.047)

Conclusion: Compared to intermediate LOS group, short and long LOS groups have greater risk of 180-day all-cause mortality or readmission. As a consequence, the more proper intra-hospital management should be applied to these 2 groups to improve clinical outcome.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are